Immunobiology of Ebola and Lassa virus infections

被引:81
|
作者
Prescott, Joseph B. [1 ]
Marzi, Andrea [1 ]
Safronetz, David [2 ,3 ]
Robertson, Shelly J. [1 ]
Feldmann, Heinz [1 ,3 ]
Best, Sonja M. [1 ]
机构
[1] NIAID, Virol Lab, Rocky Mt Labs, NIH, 903 S Fourth St, Hamilton, MT 59840 USA
[2] Publ Hlth Agcy Canada, Zoonot Dis & Special Pathogens, 1015 Arlington St, Winnipeg, MB R3E 3R2, Canada
[3] Univ Manitoba, Dept Med Microbiol, 745 Bannatyne Ave, Winnipeg, MB R3E 0J9, Canada
基金
美国国家卫生研究院;
关键词
HUMAN DENDRITIC CELLS; DOUBLE-STRANDED-RNA; HEMORRHAGIC-FEVER; VP35; PROTEIN; IMMUNE-RESPONSES; WEST-AFRICA; INTERFERON ANTAGONISM; NONHUMAN-PRIMATES; ANIMAL-MODELS; DISEASE;
D O I
10.1038/nri.2016.138
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Two of the most important contemporary emerging viruses that affect human health in Africa are Ebola virus (EBOV) and Lassa virus (LASV). The 2013-2016 West African outbreak of EBOV was responsible for more than 11,000 deaths, primarily in Guinea, Sierra Leone and Liberia. LASV is constantly emerging in these and surrounding West African countries, with an estimate of more than 500,000 cases of Lassa fever, and approximately 5,000 deaths, annually. Both EBOV and LASV are zoonotic, and human infection often results in a severe haemorrhagic fever in both cases. However, the contribution of specific immune responses to disease differs between EBOV and LASV. This Review examines innate and adaptive immune responses to these viruses with the goal of delineating responses that are associated with protective versus pathogenic outcomes.
引用
收藏
页码:195 / 207
页数:13
相关论文
共 50 条
  • [21] Immunobiology of papillomavirus infections
    Stanley, MA
    JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 2001, 52 (1-2) : 45 - 59
  • [22] IMMUNOBIOLOGY OF SKIN INFECTIONS
    WORTMANN, F
    ALLERGOLOGIE, 1987, 10 (10) : 459 - 465
  • [23] Asymptomatic Ebola virus infections-myth or reality?
    Kuhn, Jens H.
    Bavari, Sina
    LANCET INFECTIOUS DISEASES, 2017, 17 (06): : 570 - 571
  • [24] Characterization of host immune responses in Ebola virus infections
    Wong, Gary
    Kobinger, Gary P.
    Qiu, Xiangguo
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2014, 10 (06) : 781 - 790
  • [25] Lassa virus
    Günther, S
    Lenz, O
    CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 2004, 41 (04) : 339 - 390
  • [26] GILT restricts the cellular entry mediated by the envelope glycoproteins of SARS-CoV, Ebola virus and Lassa fever virus
    Chen, Danying
    Hou, Zhifei
    Jiang, Dong
    Zheng, Mei
    Li, Guoli
    Zhang, Yue
    Li, Rui
    Lin, Hanxin
    Chang, Jinhong
    Zeng, Hui
    Guo, Ju-Tao
    Zhao, Xuesen
    EMERGING MICROBES & INFECTIONS, 2019, 8 (01) : 1511 - 1523
  • [27] The deuce-ace of Lassa Fever, Ebola virus disease and COVID-19 simultaneous infections and epidemics in West Africa: clinical and public health implications
    Nnaji, Nnabueze Darlington
    Onyeaka, Helen
    Reuben, Rine Christopher
    Uwishema, Olivier
    Olovo, Chinasa Valerie
    Anyogu, Amarachukwu
    TROPICAL MEDICINE AND HEALTH, 2021, 49 (01)
  • [28] The deuce-ace of Lassa Fever, Ebola virus disease and COVID-19 simultaneous infections and epidemics in West Africa: clinical and public health implications
    Nnabueze Darlington Nnaji
    Helen Onyeaka
    Rine Christopher Reuben
    Olivier Uwishema
    Chinasa Valerie Olovo
    Amarachukwu Anyogu
    Tropical Medicine and Health, 49
  • [29] Characterization of Lassa Virus Cell Entry and Neutralization with Lassa Virus Pseudoparticles
    Cosset, Francois-Loic
    Marianneau, Philippe
    Verney, Geraldine
    Gallais, Fabrice
    Tordo, Noel
    Pecheur, Eve-Isabelle
    ter Meulen, Jan
    Deubel, Vincent
    Bartosch, Birke
    JOURNAL OF VIROLOGY, 2009, 83 (07) : 3228 - 3237
  • [30] Treatment of Ebola virus infections with inhibitors of TLR4
    Denner, Joachim
    MEDICAL HYPOTHESES, 2015, 85 (03) : 253 - 257